"Participants will be 3 thousand children aged 12 to 17": the third phase of the study of "Sputnik M" began in Moscow

In ten clinics and two children's hospitals in Moscow, the third phase of a clinical trial of the COVID-19 vaccine for adolescents, Sputnik M, has begun, said Anastasia Rakova, Deputy Mayor of the Capital for Social Development.

According to her, three thousand people aged 12-17 will take part in it.

“Already about two thousand people aged 12-17 have applied for job seekers to volunteer.

On November 8, a medical examination of the first participants began, and 208 people have already passed it.

And yesterday, the first 18 children who were screened and tested were already vaccinated.

Throughout the study, participants will be asked to keep a diary of well-being in a mobile application, and doctors will constantly monitor their condition, ”said Rakova.

In the summer, in two metropolitan hospitals - Morozov Children's Hospital and Children's Hospital.

PER.

Bashlyaeva - the first and second phases of clinical trials have started, which will last a year.

Their preliminary results indicate the effectiveness and safety of the vaccine.

“According to the results of observation of adolescents in the first two phases of the N.F.

Gamalei made a decision on the dosage of the Sputnik M vaccine for adolescents.

The vaccination will be carried out in two stages with the Sputnik M vaccine - this is the same two-component Sputnik V vaccine for people over 18 years old, but in a lower dosage: one-fifth of an adult, ”the deputy mayor explained.

On September 23, the Russian Ministry of Health announced the receipt of a package of documents for the registration of a vaccine for the prevention of COVID-19 in adolescents "Gam-COVID-Vac-M" ("Sputnik M") from the center.

Gamalei.

On September 28 it became known that the government will allocate more than 100 million rubles for the third phase of testing "Sputnik M".

Also on russian.rt.com "Based on two leading children's hospitals": a study of "Sputnik V" for adolescents began in Moscow

Morbidity and vaccination

In Russia, 40,759 new cases of coronavirus infection were recorded per day.

The total number of detected cases of COVID-19 in Russia has reached 8,952,472.

Over the past 24 hours, 1,237 deaths were registered in the country.

In total, 251 691 patients with COVID-19 have died in the Russian Federation.

7,687,317 people recovered from the coronavirus (33,156 in the last 24 hours).

The largest number of new cases of coronavirus over the past day were registered in Moscow (6240), St. Petersburg (3230) and the Moscow region (2617).

In the Russian Federation, a little more than half of elderly citizens are vaccinated against coronavirus.

This was announced by Minister of Health Mikhail Murashko at the IV All-Russian Forum "Russia - Territory of Care".

“In a pandemic, it is important to remind that it is older people who are the main risk group for the course and development of complications in COVID-19.

At the moment, slightly more than half of older people have been vaccinated, which means that still every second senior citizen of our country risks his life, because he has not yet been vaccinated, "TASS quotes him.

Earlier, he reported that more than 62 million Russians have already been vaccinated with the first component of vaccines against coronavirus, which is 53% of the adult population of the Russian Federation.

As Vladislav Zhemchugov, Doctor of Medical Sciences, a specialist in especially dangerous infections, said in an interview with Sputnik radio, the acceleration of the spread of COVID-19 and increased mortality from infection are associated with the SARS-CoV-2 mutation.

“The virus mutates from the very beginning, the current“ delta ”is not the same first Wuhan strain, as a result of this selection of mutations the virus“ accelerated ”.

The incubation period has become shorter, because, probably, the virus uses a different route of entry into the cells, the clinic has changed.

The most important thing is that the incubation period was 10-12 days, and now 3, 5, 6 (days) - and already pneumonia.

This is more lethal, because people start to heal late, ”he said.

The specialist also urged people with suspected coronavirus not to delay contacting a doctor.

“While they are thinking, while they are calling a doctor, while they are doing a test, it is already a severe form, and there are not enough places for everyone in hospitals.

It is necessary to do diagnostics earlier, start treatment from the first day, then fewer people are admitted to hospitals.

The first week should not be missed, it is necessary to start treatment during this period, ”explained Zhemchugov.

On the eve of Deputy Prime Minister Tatyana Golikova said that in total 301.5 thousand covid beds have been deployed in the Russian Federation, 82.8% of them are occupied.

A medicine to suppress the reproduction of COVID-19

Specialists of the National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya are developing a medicine to suppress the multiplication of coronavirus infection.

This was announced by the director of the institution Alexander Gintsburg.

"Those drugs that exist now - they exist, by the way, but they do not suppress the multiplication of the virus so well that they could be used to treat patients in serious condition," RIA Novosti quotes him.

He emphasized that the Gamaleya Research Center for Electrochemistry is working on a series of similar drugs: "But for them, unfortunately, I cannot promise that it will be within a few months."

Earlier, Alexander Gintsburg talked about the work on the creation of a drug from antibodies for the treatment of patients with COVID-19.

Its clinical trials are scheduled to begin in January and be completed within three to four months.

Also the day before, the press center of the Republic of Sakha reported that the biologically active additive Betukladin from birch and reindeer lichen developed in Yakutia received a certificate from the Federal Service for Supervision of Consumer Rights Protection and Human Welfare.

It is designed to prevent, facilitate and accelerate the rehabilitation of patients, in particular those who have suffered from COVID-19.

According to Boris Kershengolts, chief researcher at the Institute for Biological Problems of Cryolithozone of the Siberian Branch of the Russian Academy of Sciences, the drug reduces and facilitates the course of coronavirus, as well as stops the development of "fatigue syndrome" and depression during the rehabilitation phase.